The 2009 list of the top 20 pharmaceutical companies, ranked by IMS Health according to global prescription drug sales for the 12 months up to September 2009, shows that Teva, Novo Nordisk and Boehringer Ingelheim scored better in percent change than Big Pharma in those months.
IMS Health Top 20 pharmaceutical companies 2009
Home/Pharma News
|
Posted 23/04/2010
0
Post your comment
The data below does not take into account the large acquisitions by Pfizer and Merck, of Wyeth and Schering-Plough respectively, which were completed after September 2009.
| Company Sales | (billion US$) | % change |
| 1. Pfizer | 41.7 | (0.8) |
| 2. Novartis | 36.7 | 7.0 |
| 3. Sanofi-aventis | 35.1 | 3.3 |
| 4. GlaxoSmithKline | 34.3 | (3.4) |
| 5. AstraZeneca | 33.2 | 7.8 |
| 6. Roche | 31.3 | 8.6 |
| 7. Johnson & Johnson | 26.9 | (6.6) |
| 8. Merck & Co | 25.0 | (4.1) |
| 9. Eli Lilly | 19.6 | 8.3 |
| 10. Abbott | 19.4 | 5.5 |
| 11. Teva | 15.7 | 12.3 |
| 12. Bayer | 15.4 | 3.9 |
| 13. Wyeth | 14.8 | (2.3) |
| 14. Amgen | 14.8 | (3.1) |
| 15. Boehringer Ingelheim | 14.6 | 10.4 |
| 16. Takeda | 14.4 | 2.1 |
| 17. Bristol-Myers | 14.2 | 5.8 |
| 18. Schering-Plough | 13.1 | 4..3 |
| 19. Daiichi Sankyo | 8.5 | 3.1 |
| 20. Novo Nordisk | 8.2 | 11.6 |
References:
IMS Health
FACTBOX-The 20 largest pharmaceutical companies. Reuters. 2010 March 26.
Guidelines
Regulatory update for post-registration of biological products in Brazil
New regulations in Brazil for the registration of biosimilars
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Coherus exits the biosimilars market with sale of Udenyca to Intas Pharmaceuticals
Meitheal expands portfolio with three biosimilars through exclusive US licensing agreement
Related content
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Home/Pharma News Posted 15/01/2025
Coherus exits the biosimilars market with sale of Udenyca to Intas Pharmaceuticals
Home/Pharma News Posted 08/01/2025
Meitheal expands portfolio with three biosimilars through exclusive US licensing agreement
Home/Pharma News Posted 20/11/2024
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment